Assembly Biosciences (ASMB) EBT (2010 - 2026)

Assembly Biosciences' EBT history runs 17 years deep, the most recent figure standing at -$11.7 million for Q1 2026.

• In Q1 2026, EBT fell 17.17% year-over-year to -$11.7 million; the TTM figure through Mar 2026 stood at -$9.0 million (up 77.91% YoY), while the FY2025 annual figure was -$6.1 million, up 84.64% from the prior year.
• EBT for Q1 2026 stood at -$11.7 million, down from $22.1 million in the prior quarter.
• The five-year high for EBT was $22.1 million in Q4 2025, with the low at -$24.7 million in Q2 2022.
• The 5-year median for EBT is -$10.9 million (2023), against an average of -$12.7 million.
• The sharpest annual moves came in 2025 and 2026: EBT soared 312.18% in 2025, then retreated 17.17% in 2026.
• Assembly Biosciences' EBT stood at -$24.2 million in 2022, then surged by 54.75% to -$10.9 million in 2023, then increased by 4.74% to -$10.4 million in 2024, then soared by 312.18% to $22.1 million in 2025, then sank by 152.95% to -$11.7 million in 2026.
• Business Quant data shows ASMB's EBT at -$11.7 million in Q1 2026, $22.1 million in Q4 2025, and -$9.2 million in Q3 2025.